Smart port.
Early detection.
Better outcomes.
THE NEXT GENERATION IN REMOTE PATIENT MONITORING
Advances in Personalized Medicine and Digital Health technologies are revolutionizing modern medicine. NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
WHAT IS
NXGEN PORT?
Port efficacy + new sensor technology
Remotely measure real-time physiological distress
Digital health platform coordinating patients + providers
Early intervention
Patient management
THE
PROBLEM
COSTS $2.3 BILLION ANNUALLY
50%
Of patients on chemo with a port suffer from neutropenia which puts them at greater risk for infection and complications
20%
Of patients have complications ranging from minor to major, most frequently infections and thrombosis, leading to port removal, hospitalization, higher medical costs and treatment
25%
Of women on trastuzumab for HER2+ breast cancer suffer cardiotoxicity and cardiac function decline
50%
Of patients have to delay or cancel treatment due to poor blood counts on treatment days
THE
SOLUTION
1
REMOTE MONITORING
Physiologic changes and trends measured in vivo.
2
DATA + ANALYTICS
Real-time information about a patient's health status.
3
REPORT TO PROVIDER
Relevant measures and actionable data.
4
TAKE ACTION
Virtual patient management.
THE
VALUE
NXgen Port PROVIDES EARLY
INDICATION OF:
-
Infection
-
Changes in heart function
-
Blood cells counts
-
Oxygen levels
-
Body temperature
-
Proteins (i.e., hemoglobin)
-
Cancer prevalence
-
Device leakage or failure
PHYSICIANS
-
Early indication of infection
-
Remote patient monitoring
-
Put “eyes and hands” on patients
-
Actionable data
-
Maximize clinic time
PATIENTS
-
Baseline of health before treatment begins
-
Awareness of acceptable symptoms
-
Alert to infection Peace of mind
-
Limits “micro-traumas”
INSURANCE
PAYERS
-
Reduce unexpected hospitalizations
-
Manage costs due to adverse events
PROVIDERS
-
Reduce treatment cancelations or delays
-
Longitudinal data
-
Manage costs Increase efficiency
PHARMA
-
Virtual clinical trial support
​
-
Passive data collection
-
Adherence and drug efficacy
TEAM
Cathy Skinner, MA
Co-founder/Co-inventor
Chief Executive Officer
-
Entrepreneur with 12 years of startup experience (Thrivors.com and TheArtofWell.com).
-
Nationally recognized Cancer Exercise Specialist with the American College of Sports Medicine.
-
12 years of working face-to-face with cancer patients and survivors providing wellness programs.
-
Invited panelist and guest speaker, Cancer Survivorship Conferences, Employer Benefits, Pharma Patient Advocacy conferences.
-
Former Chair of the Minnesota Cancer Alliance.
-
Board member with one non-profit organization.
Rosanne Welcher, PhD, MBA, RAC
Co-founder/Co-inventor
Chief Operating Officer
-
Award-winning R&D and Business Leader with cross-functional expertise in Medical Devices/IVD business development, product development, regulatory and clinical affairs, quality assurance, manufacturing and commercialization.
-
Over 25 years in med devices/IVD with people management experience.
-
Former CSO Agilent Technologies, Companion Diagnostics.
-
Invited guest speaker, Personalized Medicine, Regulatory/Clinical and IVD conferences.
-
12 issued patents.
-
Board Director with two non-profit organizations.
Kelly Christian, MS
R&D and Engineering
-
30 years bringing new medical devices to market.
​
-
20 years developing new chemo ports including developing the first PowerPort (TM).
​
-
Former Senior Director at Becton Dickinson as a biomedical engineer, team leader, and program director.
​
-
Launched products with an annual value of almost a billion dollars and improved outcomes for millions of patients worldwide.
​
-
30 issued patents related to ports.
​
-
Industrial Advisory Board Member for the school of Biomedical Engineering for the University of Utah.
ADVISORS
Tufia Haddad, MD
Oncology, Product Advisor and
Patient/Physician Perspectives
John Slump
Board Chair, Investor Relations and Finance
Rich Nazarian, BS, MS
Engineering, Business Strategy and Partnerships
Serge Alexanian, MD
Medical Advisor
Surgical and Hospital Liaison
Formerly of
Nancy Lelicoff, MS
Engineering, Regulatory, Quality and Research
Formerly of
Lisa Suennen
Digital Health Strategy and Investor Relations
Alan Feinerman, PhD
Research and Device Design
Vincent Kuenen, BS, MS
Engineering, Software Development and Patient Advocate
